Matches in Wikidata for { <http://www.wikidata.org/entity/Q87076217> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q87076217 description "clinical trial" @default.
- Q87076217 description "ensayu clínicu" @default.
- Q87076217 description "klinisch onderzoek" @default.
- Q87076217 description "клінічне випробування" @default.
- Q87076217 name "Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers" @default.
- Q87076217 name "Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers" @default.
- Q87076217 type Item @default.
- Q87076217 label "Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers" @default.
- Q87076217 label "Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers" @default.
- Q87076217 prefLabel "Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers" @default.
- Q87076217 prefLabel "Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers" @default.
- Q87076217 P1132 Q87076217-C4D837F6-ED23-40E4-8F71-73FD278417B6 @default.
- Q87076217 P1476 Q87076217-B5EAA101-987A-4704-868F-CD5E9A2E9BF1 @default.
- Q87076217 P17 Q87076217-DC5E73DD-EB70-4F7C-90D9-A6CA2B1094B0 @default.
- Q87076217 P1813 Q87076217-4280B20B-1ACD-4DBE-AD4D-7A27D8FE5F92 @default.
- Q87076217 P2899 Q87076217-C37DE9CA-0D8F-4B28-8015-C443560457CB @default.
- Q87076217 P3098 Q87076217-BE97C0C0-CF44-44B1-9693-E173944377BC @default.
- Q87076217 P31 Q87076217-8BFB86D6-6F85-47BE-A807-7E8F836A9CF1 @default.
- Q87076217 P4844 Q87076217-2807AFBC-5801-49D4-9571-39F1B17FE6B7 @default.
- Q87076217 P4844 Q87076217-A2FC2C55-7B9D-4040-8064-AB74502BDB84 @default.
- Q87076217 P580 Q87076217-C773F7BE-DF6F-4DBB-9BF9-C62CB9D64899 @default.
- Q87076217 P582 Q87076217-30A9B375-EE4E-457D-A890-9DE3A9B5C61C @default.
- Q87076217 P6099 Q87076217-34A3C4D9-D695-479D-B595-51535208BB2A @default.
- Q87076217 P8363 Q87076217-371E7446-CA64-4212-9437-3CB1F62B7222 @default.
- Q87076217 P1132 "+72" @default.
- Q87076217 P1476 "A Phase I Trial Assessing the Safety and Efficacy of an Anti-tumor Immunity Priming Strategy Combining Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers" @default.
- Q87076217 P17 Q142 @default.
- Q87076217 P1813 "PRIMO" @default.
- Q87076217 P2899 "+18" @default.
- Q87076217 P3098 "NCT04270864" @default.
- Q87076217 P31 Q30612 @default.
- Q87076217 P4844 Q2459042 @default.
- Q87076217 P4844 Q7041828 @default.
- Q87076217 P580 "2020-02-01T00:00:00Z" @default.
- Q87076217 P582 "2024-02-01T00:00:00Z" @default.
- Q87076217 P6099 Q5452194 @default.
- Q87076217 P8363 Q78089383 @default.